CRVS
Corvus Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +28.6% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 34.72M | $518.70M | +11 | −5 |
| Q1 2026 | 64 | +8 | 30.80M | $450.00M | +15 | −7 |
| Q4 2025 | 56 | +2 | 25.04M | $192.77M | +2 | n/a |
| Q3 2025 | 14 | 0 | 18.71M | $137.91M | +2 | −2 |
| Q2 2025 | 11 | -1 | 17.31M | $69.23M | +1 | −2 |
| Q1 2025 | 9 | +2 | 6.14M | $19.53M | +2 | n/a |
| Q4 2024 | 7 | -1 | 4.46M | $23.85M | n/a | −1 |
| Q3 2024 | 7 | 0 | 7.32M | $38.63M | n/a | n/a |
| Q2 2024 | 7 | n/a | 7.37M | $13.41M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 2.79M | -8.0% | $8.86M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Millennium Management ✦ | 1.64M | +956.9% | $5.21M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 590.29K | +4.1% | $1.88M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Two Sigma Investments ✦ | 308.35K | +917.5% | $980,553 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 264.99K | -32.2% | $842,662 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 230.04K | +11.9% | $731,521 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Marshall Wace ✦ | 154.77K | New | $492,172 | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 104.87K | New | $333,493 | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 61.68K | -21.6% | $196,130 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $492,172 | 0.0% |
| Wellington Management | $333,493 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 163 holders, 69.83M shares, $976.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.